iShares NASDAQ Biotechnology Index (IBB) Receiving Positive News Coverage, Study Shows

News headlines about iShares NASDAQ Biotechnology Index (NASDAQ:IBB) have trended positive this week, Accern reports. The research group identifies negative and positive news coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. iShares NASDAQ Biotechnology Index earned a coverage optimism score of 0.35 on Accern’s scale. Accern also assigned news articles about the financial services provider an impact score of 45.6596387342635 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

These are some of the media stories that may have impacted Accern’s scoring:

Shares of iShares NASDAQ Biotechnology Index (NASDAQ:IBB) traded down $0.40 during trading hours on Friday, hitting $110.36. The stock had a trading volume of 1,926,950 shares, compared to its average volume of 3,330,000. iShares NASDAQ Biotechnology Index has a 12-month low of $94.20 and a 12-month high of $119.30. The company has a market cap of $9,670.00, a price-to-earnings ratio of 3.64 and a beta of 1.37.

ILLEGAL ACTIVITY WARNING: “iShares NASDAQ Biotechnology Index (IBB) Receiving Positive News Coverage, Study Shows” was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this article on another publication, it was illegally copied and republished in violation of United States & international trademark and copyright law. The legal version of this article can be read at https://www.dispatchtribunal.com/2018/02/18/ishares-nasdaq-biotechnology-index-ibb-receiving-positive-news-coverage-study-shows.html.

About iShares NASDAQ Biotechnology Index

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.

Insider Buying and Selling by Quarter for iShares NASDAQ Biotechnology Index (NASDAQ:IBB)

Receive News & Ratings for iShares NASDAQ Biotechnology Index Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares NASDAQ Biotechnology Index and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply